NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Reports Third Quarter 2018 Financial Results
-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second Cell-Free ADC Addressing Unmet Medical Need in Oncology SOUTH SAN FRANCISCO, Calif., Nov. 13, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the U.S. Food and Drug...
Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
Sharp to Bring Additional Financial Expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., Nov. 8, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Shalini Sharp, Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical...
Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018-- Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for STRO-001 for the treatment of...
Sutro Biopharma Announces $85.0 Million Initial Public Offering
South San Francisco, California – September 26, 2018. Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF+™, to create a broad...
12th Biennial Ovarian Cancer Research Symposium – STRO-002 Abstract
Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, and is thus a promising target for cancer therapy using antibody drug conjugates (ADCs). Most ADCs currently in development are...
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created post of chief people and communications officer. Mr. Worsley has over 25 years of biotechnology...
Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment
Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat...
12th Biennial Ovarian Cancer Research Symposium – STRO-002 Poster
Preclinical Activity and Safety of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian Cancer
Sutro Biopharma Announces $85.4 Million Series E Round
Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its...